Bayer and Onyx Amgen reports phase 3 study results of NEXAVAR


Tuesday, 11 Mar 2014 03:30am EDT 

Amgen Inc:Says HealthCare Pharmaceuticals Inc and Onyx Pharmaceuticals Inc, an Amgen subsidiary finished trial evaluating investigational use of NEXAVAR did not meet its primary endpoint.Report phase 3 study results of NEXAVAR (sorafenib) as adjuvant treatment for patients with liver cancer who have undergone surgery or local ablation.Safety findings were consistent with the known profile of sorafenib.Data from this study will be submitted for presentation at an upcoming scientific congress. 

Company Quote

162.59
2.04 +1.27%
27 Mar 2015